Combination inhibition of the renin-angiotensin system: Is more better

Kidney International

Volumn 80, Issue 3, 2011, Pages 245-255

  Krause, Michelle W ^a   Fonseca, Vivian A ^b   Shah, Sudhir V ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ACE inhibitors; angiotensin; cardiovascular disease; chronic kidney disease

Indexed keywords

ALBUMIN; ALISKIREN; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; BRADYKININ; CANDESARTAN; CAPTOPRIL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; PLACEBO; RAMIPRIL; RENIN; TELMISARTAN; TRANDOLAPRIL; VALSARTAN; VERAPAMIL;

ACUTE HEART INFARCTION; ALBUMINURIA; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DRUG DOSE TITRATION; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYPERTENSION; HYPOTENSION; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; KIDNEY POLYCYSTIC DISEASE; MACROALBUMINURIA; MICROALBUMINURIA; MONOTHERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROTEINURIA; REMISSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; STROKE; SYNCOPE; VASODILATATION;

EID: 79960392722     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.142     Document Type: Review

References (101)

1. Bright R. Tubular view of the morbid appearances in 100 cases connected with albuminous urine: with observations. Guy's Hops Rep 1836; 1: 380-400.
2. Mahomed FA. The physiology and clinical use of the sphygmograph. Med Times Gaz 1872; 1: 62-64.
3. Riva-Rocci S. Un sfigmomanometro nuovo. Gazetta Medica di Torino 1896; 47: 981-986.
4. Korotkoff NS. On methods of studying blood pressure [in Russian]. Bull Imperial Mil Med Acad 1905; 11: 365-367.
5. Tigerstedt R, Bergman PG. Niere Und Kreislauf. Skand Arch Physiol 1898; 8: 223-227.
6. Goldblatt H, Lynch J, Hanzal RF et al. Studies on experimental hypertension. The production of persistent elevation of systolic blood pressure by means of renal ischaemia. J Exp Med 1934; 59: 347-379.
7. Werle E. Discovery of the most important kallikreins and kallikrein inhibitors. Erdos EG (eds). Bradykinin, Kallidin, and Kallikrein Handbook of Experimental Pharmacology. Springer Verlag: Berlin, 1970, XXV 1-6.
8. Leloir LF, Munoz JM, Braun-Menendez E et al. La secretion de la renina y la formacion de hipertensina. Rev Soc Arg Biol 1940; 16: 75-80.
9. Kohlstaedt KG, Helmer OM, Page IH. Activation of renin by blood colloids. Proc Soc Exp Biol Med 1938; 39: 214-215.
10. Skeggs LT, Dorer FE, Kahn JR et al. Experimental renal hypertension: the discovery of the renin-angiotensin system. Soffer R (eds). Biochemical Regulation of Blood Pressure. John Wiley & Sons: Hoboken, 1981: 3-38.
11. Tacquini Jr AC, Taquini AC. The renin-angiotensin system in hypertension. Am Heart J 1961; 62: 558-564.
12. Ferreira SH, Greene LJ, Alabaster VA et al. Activity of various fractions of bradykinin potentiating factor against angiotensin I converting enzyme. Nature 1970; 225: 379-380.
13. Erdö s EG, Yang HY. An enzyme in microsomal fraction of kidney that inactivates bradykinin. Life Sci 1967; 6: 569-574.
14. Case DB, Atlas SA, Laragh JH et al. Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting enzyme inhibitor (SQ 14,225, captopril) in hypertensive patients. Prog Cardiovasc Dis 1978; 21: 195-206. (Pubitemid 9068240)
15. Yoshiyasu F, Kishimoto S, Nishikawa K. Hypotensive imidazole derivatives. US Patent 1982; 4: 340-598.
16. Swedberg K, Eneroth P, Kjekshus J, and the CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990; 82: 1730-1736. (Pubitemid 20367976)
17. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 2002; 89: 3A-9A.
18. Schieffer B, Bü nte C, Witte J et al. Comparative effects of AT-1 antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol 2004; 44: 362-368. (Pubitemid 38960662)
19. Unger T, Stoppelhaar M. Rationale for double renin- angiotensinaldosterone-system blockade. Am J Cardiol 2007; 100: 25J-31J.
20. Brunner HR, Laragh JH, Baer L et al. Essential hypertension: renin and aldosterone, heart attack, and stroke. N Engl J Med 1972; 286: 441-449.
21. Azizi M, Linhart A, Alexander J et al. Pilot study of combined blockade of the renin-angiotensin system in essential hypertensive patients. Hypertension 2000; 18: 1139-1147.
22. Stergiou GS, Skeva II, Baibas NM et al. Additive hypotensive effect of angiotensin-converting enzyme inhibition and angiotensin-receptor antagonism in essential hypertension. Cardiovasc Pharmacol 2000; 35: 937-941. (Pubitemid 30327525)
23. Weir MR, Smith DH, Neutel JM et al. Valsartan alone or with a diuretic or ACE inhibitor as treatment for African American hypertensives: relation to salt intake. Am J Hypertens 2001; 14: 665-671. (Pubitemid 32612531)
24. Morgan T, Anderson A, Bertrem D et al. Effect of candesartan and lisinopril alone and in combination on blood pressure and microalbuminuria. J Renin Angiotensin Aldosterone Syst 2004; 5: 64-74.
25. Weir MR, Weber MA, Neutel JM, for the ACTION Study Investigators. Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: a clinical experience trial. Am J Hypertens 2001; 14: 567-572. (Pubitemid 32506731)
26. Schulte KL, Fischer M, Meyer-Sabellek W. Efficacy and tolerability of candesartan cilexetil monotherapy or in combination with other antihypertensive drugs. Results of the AURA study. Clin Drug Invest 1999; 18: 453-460. (Pubitemid 30047532)
27. Izzo JL, Weinberg MS, Hainer JW et al. Antihypertensive efficacy of candesartan-lisinopril in combination vs up-titration of lisinopril: the AMAZE trials. J Clin Hypertens 2004; 6: 485-493.
28. Doulton TW, He FJ, MacGregor GA. Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 2005; 45: 880-886. (Pubitemid 40628932)
29. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559.
30. Berl T, Hunsicker LG, Lewis JB, for the Collaborative Study Group. Impact of achieved blood pressure on cardiovascular outcomes in the irbesartan diabetic nephropathy trial. J Am Soc Nephrol 2005; 16: 2170-2179. (Pubitemid 41716450)
31. Thune JJ, Signorovitch J, Kober L et al. Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction. Hypertension 2008; 51: 48-54. (Pubitemid 350307103)
32. Messerli FH. The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point. J Am Coll Cardiol 2009; 53: 468-470.
33. Heart and Stroke Foundation. Guideline alert for blood pressure patients as treatment combo (press release). Heart and Stroke Foundation, 2009; http://www.heartandstroke.com.
34. McKelvie RS, Yusuf S, Pericak D et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Circulation 1999; 100: 1056-1064. (Pubitemid 29416231)
35. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-1675. (Pubitemid 33126822)
36. Granger CB, McMurray JJ, Yusuf S, for the CHARM Investigators. Effects of candesartan in patients with chronic heart failure and reduced leftventricular systolic function intolerant to angiotensin-convertingenzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772-776. (Pubitemid 37093917)
37. Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777-781. (Pubitemid 37093918)
38. McMurray JJ, Ö stergren J, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARMAdded trial. Lancet 2003; 362: 767-771. (Pubitemid 37093916)
39. Dickstein K, Cohen-Solal A, Filippatos G, for the Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29: 2388-2442.
40. Jessep M, Abraham WT, Casey DE, for the 2005 Heart Failure Writing Committee. 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119: 1972-2016.
41. Pfeffer MA, McMurray J, Velazquez EJ, for the Valsartan in acute myocardial infarction trial investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-1906. (Pubitemid 37409706)
42. Baker WL, Coleman CI, Kluger J et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease. Ann Intern Med 2009; 151: 861-871.
43. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998; 339: 1448-1456. (Pubitemid 28516069)
44. Ruiz-Ortega M, Lorenzo O, Suzuki Y et al. Pro-inflammatory actions of angiotensins. Curr Opin Nephrol Hypertens 2001; 10: 321-329.
45. Remuzzi G, Perico N, Macia M et al. The role of renin- angiotensinaldosterone system in the progression of chronic kidney disease. Kidney Int 2005; 68: S57-S65.
46. Lewis EJ Hunsicker LG, Bain RP et al. The effect of angiotensinconverting enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-1462. (Pubitemid 23335891)
47. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus. Results of the HOPE Study and MICRO-HOPE Sub-Study. Lancet 2000; 355: 253-259.
48. Lewis EJ, Hunsicker LG, Clarke WR, for the Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
49. Brenner BM, Cooper ME, de Zeeuw D, for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
50. Parving HH, Lehnert H, Bröchner-Mortensen J, for the Irbesartan in patients with type 2 diabetes and microalbuminuria study group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
51. Mogensen CE, Neldam S, Tikkanen I, for the CALM Study group. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and noninsulin dependent diabetes: the Candesartan and Lisinopril Microalbuminuria (CALM) study. BMJ 2000; 321: 1440-1444.
52. Rossing K, Jacobsen P, Pietraszek L et al. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy. Diabetes Care 2003; 26: 2268-2274. (Pubitemid 36993311)
53. Jacobsen P, Andersen S, Jensen BR et al. Additive effect of ACE inhibition and angiotensin II receptor blockade in type i diabetic patients with diabetic nephropathy. J Am Soc Nephrol 2003; l4: 992-999. (Pubitemid 36359280)
54. Jacobsen P, Andersen S, Rossing K et al. Dual blockade of the reninangiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 2003; 63: 1874-1880. (Pubitemid 36513336)
55. Jennings DL, Kalus JS, Coleman CI et al. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. Diabetes Med 2007; 24: 486-493. (Pubitemid 46669317)
56. Andersen NH, Poulsen PL, Knudsen T et al. Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study. Diabetes Care 2005; 28: 273-277. (Pubitemid 40170925)
57. Bakris GL, Ruilope L, Locatelli F et al. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int 2007; 72: 879-885. (Pubitemid 47462081)
58. Casas JP, Chua W, Loukogeorgakis S et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005; 366: 2026-2033. (Pubitemid 41773378)
59. Mann J, Schmieder RE, McQueen M, on behalf of the ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomized, double-blind, controlled trial. Lancet 2008; 372: 547-553.
60. Parving HH, Brenner BM, McMurray JJ et al. Dual renin-angiotensin system blockade and kidney disease. J Am Coll Cardiol 2009; 54: 278-279.
61. Abutaleb N. ONTARGET should not be over interpreted. Nephrol Dial Transplant 2010; 25: 44-47.
62. Ruggenenti P, Remuzzi G. Proteinuria: Is the ONTARGET renal substudy actually off target? Nat Rev Nephrol 2009; 5: 436-437.
63. Poggio ED, Wang X, Greene T et al. Performance of the modification of diet in renal disease and Cockcroft-Gault study equations in the estimation of GFR in health and in chronic kidney disease. J Am Soc Nephrol 2005; 16: 459-466. (Pubitemid 41725142)
64. Rule AD, Larson TS, Bergstralh EJ et al. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med 2004; 141: 929-937.
65. Wright JT, Bakris G, Greene T, for the African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. JAMA 2002; 288: 2421-2431. (Pubitemid 35340538)
66. Ishani A, Xue JL, Himmelfarb J et al. Acute kidney injury increases risk of ESRD among elderly. J Am Soc Nephrol 2009; 20: 223-228.
67. Ruggenenti P, Perticucci E, Cravedi P et al. Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol 2008; 19: 1213-1224.
68. Psaty BM, Lumley T. Surrogate end points and FDA approval. A tale of 2 lipid-altering drugs. JAMA 2008; 299: 1474-1476. (Pubitemid 351468448)
69. Fleming TR. Surrogate endpoints and FDA's accelerated approval process. Health Affairs 2005; 24: 67-78. (Pubitemid 40173935)
70. Khosla N, Sarafidis PA, Bakris GL. Microalbuminuria. Clin Lab Med 2006; 26: 635-653. (Pubitemid 44287154)
71. Glassock RJ. Debate: CON position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol 2010; 31: 462-465.
72. Weir MR, Bakris GL. Editorial perspective. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol 2010; 31: 469-470.
73. Levey AS, Cattran D, Friedman A et al. Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 2009; 54: 205-226.
74. Freid L, Duckworth W, Zhang JH, for the VA Nephron-D Investigators. Combination angiotensin receptor blockers and angiotensin converting enzyme inhibitor for the treatment of diabetic nephropathy VA Nephron-D study. Clin J Am Soc Nephrol 2008; 4: 361-368.
75. Parving HH, Brenner BM, McMurray JJ et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009; 5: 1663-1671.
76. Dillon JJ. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for IgA nephropathy. Sem Nephrol 2004; 24: 218-224. (Pubitemid 38685991)
77. Russo D, Minutolo R, Pisani A et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 2001; 38: 18-25. (Pubitemid 32611753)
78. Tylicki L, Rutkowski P, Renke M et al. Renoprotective effect of small doses of losartan and enalapril in patients with primary glomerulonephritis. Am J Nephrol 2002; 22: 356-362.
79. Rutkowski P, Tylicki L, Renke M et al. Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis. Am J Kidney Dis 2004; 43: 260-268. (Pubitemid 38146324)
80. Nakao N, Yoshimura A, Morita H et al. Combination Treatment of Angiotensin II Receptor Blocker and Angiotensin-Converting-Enzyme Inhibitor in Non-Diabetic Renal Disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361: 117-124. (Pubitemid 36092015)
81. Bidani A. Controversy about COOPERATE ABPM trial data. Letter to the Editor. Am J Nephrol 2006; 26: 629-632.
82. Kunz R, Wolbers M, Glass T et al. The COOPERATE trial: a letter of concern. Lancet 2008; 371: 1575.
83. Catapano F, Chiodini P, De Nicola L et al. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression. Am J Kidney Dis 2008; 52: 475-485.
84. Kunz R, Friedrich C, Wolbers M et al. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the reninangiotensin system on proteinuria in renal disease. Ann Intern Med 2008; 148: 30-48. (Pubitemid 351688350)
85. Chapman AB, Torres VE, Perrone RD et al. The HALT Polycystic kidney disease trials. Design and implementation. Clin J Am Soc Nephrol 2010; 5: 102-109.
86. Maione A, Nicolucci A, Craig JC et al. LIRICO study group. Protocol of the Long-term Impact of RAS Inhibition on Cardiorenal Outcomes (LIRICO) randomized trial. J Nephrol 2007; 20: 646-655. (Pubitemid 351266118)
87. Berl T. Maximizing inhibition of the renin-angiotensin system with high dose of converting enzyme inhibitors or angiotensin receptor blockers. Nephrol Dial Transplant 2008; 23: 2443-2447.
88. Hou FF, Xie D, Zhang X et al. Renoprotection of optimal antiproteinuric doses (ROAD) study: a randomized controlled study of benezapril and losartan in chronic renal insufficiency. J Am Soc Nephrol 2007; 18: 1889-1898. (Pubitemid 46870325)
89. Burgess E, Muirhead N, Rene De Cotret P. A double-blind randomized controlled trial of high dose candesartan cilexetil in proteinuria renal disease results from SMART (Supra maximal atacand renal trial). J Am Soc Nephrol 2009; 20: 893-900.
90. Fisher N, Hollenberg NK. Renin inhibition: what are the therapeutic opportunities. J Am Soc Nephrol 2005; 16: 592-599. (Pubitemid 41725095)
91. Solomon S. Effect of the direct renin inhibitor aliskiren on left ventricular remodeling following myocardial infarction with left ventricular dysfunction: ASPIRE. Am Coll Cardiol 2010 Abstract 3019-3010.
92. Parving HH, Persson F, Lewis JB, for the AVOID study investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433-2446. (Pubitemid 351793017)
93. Alfrey AC, Froment DH, Hammond WS. Role of iron in the tubulointerstitial injury in nephrotoxic serum nephritis. Kidney Int 1989; 36: 753-759. (Pubitemid 19283272)
94. Lin JL, Lin-Tan DT, Hsu KH et al. Environmental lead exposure and progression of chronic renal disease in patients without diabetes. N Engl J Med 2003; 348: 277-286.
95. Cho ME, Smith DC, Branton MH et al. Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2007; 2: 906-913.
96. Waandeis F, Vaidya VS, van Goor H et al. Effect of renin- angiotensinaldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in non diabetic proteinuric kidney disease: a post hoc analysis of a randomized controlled trial. Am J Kidney Dis 2009; 53: 16-25.
97. Bolignano D, Lacquamiti A, Coppolino G et al. Neutrophil gelatinaseassociated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 337-344.
98. Bolignano D, Coppolino G, Campo S et al. Urinary neutrophil gelatinase-associated lipocalin (NGAL) is associated with severity of renal disease in proteinuric patients. Nephrol Dial Transplant 2008; 23: 414-416. (Pubitemid 351767366)
99. Perico N, Cattaneo D, Remuzzi G. Kidney injury molecule 1: in search of biomarkers of chronic tubulointerstitial damage and disease progression. Am J Kidney Dis 2009; 53: 1-14.
100. Kamijo A, Sugaya T, Hikawa A et al. Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease: a multicenter trial. J Lab Clin Med 2005; 145: 125-133. (Pubitemid 40432361)
101. Kamijo-Ikemori A, Sugaya T, Kimura K. Urinary fatty acid binding protein in renal disease. Clin Chim Acta 2006; 374: 1-7. (Pubitemid 44572240)